May 14, 2019 / 06:30AM GMT
Daniel Schneider - PhotoCure ASA - President & CEO
Welcome to Photocure's first quarter 2019 update. I'm Dan Schneider, President and CEO. With me today also is Erik Dahl, the CFO for Photocure.
I'll take you through a number of slides kicking off and then I'll hand it over to Erik for financials and I'll wrap up at the end, if that's okay. All right. Reminder, today as usual disclaimers are in effect for today's presentation. So 2019 objectives, simply put this is going to be a year about focused execution but we're off to a great start. Q1 revenue growth in the US was up 52% and in market volume up 44%. This is the highest unit and revenue quarter to date for Photocure. We had a 51% growth in year-over-year installed Blue Light enabled cystoscopes in the market bringing the total to 171, of which 11 are flex cystoscopes and I'll talk a little more about the process of getting these scopes put into hospitals. It does take time. It is not an easy process. It's complicated and time consuming.
Total Hexvix/Cysview revenue increased 26% year-over-year to NOK 51.2 million. This is the
Q1 2019 Photocure ASA Earnings Call Transcript
May 14, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers